Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
HOPKINTON, Mass., Sept. 06, 2016 -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced that two abstracts related to SB 11285, the Company’s novel, proprietary STING agonist compound for immuno-oncology, have been accepted for poster presentations at the upcoming American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy taking place on October 20-23, 2016 at the Boston Marriott Copley Place in Boston, MA. These abstracts highlight the potent immune-modulating and anti-tumor activities of SB 11285 in multiple in vitro systems.
The titles of the Spring Bank poster presentations are as follows:
- Nucleotide Analogs as Novel STING Agonists for Immuno-oncology
- Novel dinucleotides that activate STING signaling for Immuno-oncology
Further details about the dates and times, abstract numbers, and locations for the poster presentations will be provided when these details are made available by AACR.
About the American Association for Cancer Research
The mission of the American Association for Cancer Research is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus.
Contact: Jon Freve Chief Financial Officer (508) 500-4956 [email protected]
